1. Home
  2. AURA vs CTKB Comparison

AURA vs CTKB Comparison

Compare AURA & CTKB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AURA
  • CTKB
  • Stock Information
  • Founded
  • AURA 2007
  • CTKB 1990
  • Country
  • AURA United States
  • CTKB United States
  • Employees
  • AURA N/A
  • CTKB N/A
  • Industry
  • AURA Biotechnology: Pharmaceutical Preparations
  • CTKB Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • Sector
  • AURA Health Care
  • CTKB Health Care
  • Exchange
  • AURA Nasdaq
  • CTKB Nasdaq
  • Market Cap
  • AURA 396.8M
  • CTKB 433.8M
  • IPO Year
  • AURA 2021
  • CTKB 2021
  • Fundamental
  • Price
  • AURA $6.00
  • CTKB $3.94
  • Analyst Decision
  • AURA Strong Buy
  • CTKB Hold
  • Analyst Count
  • AURA 7
  • CTKB 4
  • Target Price
  • AURA $22.29
  • CTKB $6.00
  • AVG Volume (30 Days)
  • AURA 283.0K
  • CTKB 906.5K
  • Earning Date
  • AURA 11-11-2025
  • CTKB 11-04-2025
  • Dividend Yield
  • AURA N/A
  • CTKB N/A
  • EPS Growth
  • AURA N/A
  • CTKB N/A
  • EPS
  • AURA N/A
  • CTKB N/A
  • Revenue
  • AURA N/A
  • CTKB $196,035,000.00
  • Revenue This Year
  • AURA N/A
  • CTKB N/A
  • Revenue Next Year
  • AURA N/A
  • CTKB $7.25
  • P/E Ratio
  • AURA N/A
  • CTKB N/A
  • Revenue Growth
  • AURA N/A
  • CTKB N/A
  • 52 Week Low
  • AURA $4.35
  • CTKB $2.37
  • 52 Week High
  • AURA $12.38
  • CTKB $7.63
  • Technical
  • Relative Strength Index (RSI)
  • AURA 35.91
  • CTKB 51.09
  • Support Level
  • AURA $5.93
  • CTKB $3.71
  • Resistance Level
  • AURA $6.28
  • CTKB $4.04
  • Average True Range (ATR)
  • AURA 0.25
  • CTKB 0.21
  • MACD
  • AURA -0.03
  • CTKB 0.03
  • Stochastic Oscillator
  • AURA 0.00
  • CTKB 66.02

About AURA Aura Biosciences Inc.

Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.

About CTKB Cytek Biosciences Inc.

Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Cytek Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its FSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance. Geographically, the company generates a majority of its revenue from the United States.

Share on Social Networks: